SCIENTIFIC HUB

Follow the evidence.

SCIENTIFIC LITERATURE · MED

Automated radiosynthesis and clinical experience of [<sup>18</sup>F]SMBT-1 PET imaging for <i>in vivo</i> evaluation of reactive astrocyte in Parkinson's disease: a pilot study.

Front Nucl Med · 2025-12-08

DOI: 10.3389/fnume.2025.1718255PMID: 41437980

Open accessresearch-article; Journal ArticleOriginal source ↗

Research overview

The text below is the source article’s original abstract under a verified reuse license. cc by

BackgroundNeuroinflammation plays an important role in progression of Parkinson disease (PD). [18F]SMBT-1 is a promising novel radiotracer for in vivo evaluation of reactive astrogliosis.MethodsThe automated radiosynthesis of [18F]SMBT-1 was optimized and performed production by using the Synthra RNplus synthesizer module, and the quality of the labeled tracer was evaluated. Total 5 participants, 2 PD and 3 Healthy Control were enrolled. Cognitive assessments were performed in all participants while H&Y scales and MDS-UPDRS were performed only in PD. All participants underwent [18F]SMBT-1 PET/MRI and [18F]FDOPA PET/CT within 2-week intervals. Demographic and imaging data were collected. The correlation between [18F]FDOPA uptake and [18F]SMBT-1 uptake was analyzed by Spearman's correlation.Results[18F]SMBT-1 was successfully synthesized via nucleophilic substitution of a tosylate precursor, followed by a deprotection step. After purification and formulation, [18F]SMBT-1 was obtained with an average decay-corrected radiochemical yield of 36.56 ± 11.55% and molar activity as 396 Gbq/μmol at the end of synthesis (n = 7). Moderate PD defined by the [18F]FDOPA showed increased [18F]SMBT-1 in prefrontal cortex, temporal lobes, striatum, thalamus, pons, medullar, and midbrain while severe PD showed globally increased [1⁸F]SMBT-1. Healthy control also showed globally increased [18F]SMBT-1 uptake. There was no significant correlation between the degree of [18F]FDOPA uptake and [18F]SMBT-1 uptake in any brain region.ConclusionThe automated radiosynthesis of [18F]SMBT-1 are suitable for routine production without any immediate complication reported after administration. Moderate PD shows decreased astrocyte function as they lose neuroprotective astrocytes while severe PD shows increased astrocyte function as increased neurotoxic astrocytes.

Scientific assessment

01

Research question

Assess the question within the original study’s scope.

02

Methods & sample

Check the source article for study design and sample details.

03

Key findings

An editorially approved findings summary is not yet published for this record.

04

Limitations

Generalizability, bias and clinical meaning require separate assessment.

Methods, samples and clinical conclusions are not inferred from bibliographic metadata.